Autophagy in hepatocellular carcinomas: from pathophysiology to therapeutic response

Srikanta Dash,1,2 Srinivas Chava,1 Partha K Chandra,1 Yucel Aydin,2 Luis A Balart,2 Tong Wu1 1Department of Pathology and Laboratory Medicine, 2Department of Gastroenterology and Hepatology, Tulane University School of Medicine, New Orleans, LA, USA Abstract: Autophagy is an intracellular lysosomal...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Dash S, Chava S, Chandra PK, Aydin Y, Balart LA, Wu T
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://doaj.org/article/f0d2280ef3934939957b0585dde38b5c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Srikanta Dash,1,2 Srinivas Chava,1 Partha K Chandra,1 Yucel Aydin,2 Luis A Balart,2 Tong Wu1 1Department of Pathology and Laboratory Medicine, 2Department of Gastroenterology and Hepatology, Tulane University School of Medicine, New Orleans, LA, USA Abstract: Autophagy is an intracellular lysosomal degradation process performed by the cells to maintain energy balance. The autophagy response plays an important role in the progression of liver disease due to hepatitis virus infection, alcoholic liver disease, nonalcoholic fatty liver disease, liver cirrhosis, and hepatocellular carcinoma (HCC). An increased autophagy response also contributes to the pathogenesis of liver disease through modulation of innate and adaptive immune responses; a defective cellular autophagy response leads to the development of HCC. Recent progress in the field indicates that autophagy modulation provides a novel targeted therapy for human liver cancer. The purpose of this review is to update our understanding of how the cellular autophagy response impacts the pathophysiology of liver disease and HCC treatment. Keywords: hepatocellular carcinoma, macroautophagy, microautophagy, autophagy inhibitor, chloroquine, hydroxychloroquine, sorafenib